Lung transplantation is severely constrained by organ scarcity — and a significant fraction of otherwise viable donor lungs are discarded because vascular injury triggers edema that makes them unsuitable. Any intervention that could stabilize these organs during the preservation window before transplant would represent a meaningful advance in transplant medicine, potentially expanding the donor pool and improving recipient outcomes.
This paired split-lung study evaluated CYM5442, a selective agonist for sphingosine-1-phosphate receptor 1 (S1PR1), administered during six hours of ex vivo lung perfusion (EVLP) in seven sets of human donor lungs declined for transplant. Using one lobe as a treated arm and the contralateral lobe as an internal control — a design that elegantly eliminates donor-to-donor variability — the researchers found CYM5442 significantly reduced vascular permeability as measured by Evans blue dye accumulation in both bronchoalveolar lavage fluid and lung tissue. Treated lungs also showed attenuated weight gain, lower ultrasound-derived lung water scores, and reduced pulmonary artery and peak airway pressures. At the molecular level, CYM5442 preserved vascular endothelial cadherin — a key junctional protein maintaining barrier integrity — while suppressing pro-inflammatory cytokines interleukin-6 and interleukin-1 beta at multiple time points.
S1PR1 signaling is an established regulator of endothelial barrier function; activation tightens intercellular junctions and counters cytokine-driven permeability. What makes this work noteworthy is the translation into a human organ model under clinically relevant conditions, rather than animal or cell-culture systems. The split-lung design is methodologically rigorous for a feasibility study, though the n=7 cohort is small and no functional transplant outcomes were measured — the lungs remained on the perfusion circuit rather than being implanted. The practical implication is that pharmacological S1PR1 agonism during EVLP could rehabilitate marginal donor lungs, expanding an acutely scarce resource. Replication in larger series and, ultimately, transplant survival data will be required to assess clinical translation.